General Practice · Naranjuo, PR
NPI
1366492225
Since 2006
Specialty
General Practice
Code 208D00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
Calle Georgetti, #139, Suite 1
Naranjuo, PR, 00719
Phone (787) 869-6086
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$208K
11,430 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Melito Reategui Montoya prescribed most often to Medicare patients was Gabapentin, with 791 prescriptions and refills. In total Melito Reategui Montoya wrote 11,430 Medicare prescriptions that cost $208K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-01-11.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Gabapentin Generic | 791 | 823 | 73 | $4,494 |
| Metformin Hcl Generic | 558 | 601 | 61 | $1,874 |
| Sulindac Generic | 553 | 555 | 87 | $7,409 |
| Atorvastatin Calcium Generic | 550 | 574 | 64 | $3,221 |
| Simvastatin Generic | 520 | 563 | 61 | $2,453 |
| Famotidine Generic | 494 | 529 | 66 | $2,397 |
| Alendronate Sodium Generic | 473 | 496 | 61 | $2,331 |
| Lisinopril Generic | 460 | 489 | 55 | $1,488 |
| Amlodipine Besylate Generic | 372 | 398 | 43 | $1,170 |
| Levothyroxine Sodium Generic | 362 | 370 | 38 | $2,762 |
| Montelukast Sodium Generic | 351 | 363 | 39 | $2,270 |
| Omeprazole Generic | 318 | 330 | 40 | $1,407 |
| Hydrochlorothiazide Generic | 311 | 345 | 41 | $1,108 |
| Losartan Potassium Generic | 296 | 306 | 34 | $1,945 |
| Clonazepam Generic | 202 | 202 | 28 | $1,907 |
Brand drugs: 443 claims; generic drugs: 10,891 claims; opioid claims: 93.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Melito Reategui Montoya were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.